# US 2025/0375391 A1 · Lipid nanoparticle compositions comprising surface lipid derivatives and relates uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375391 A1
- Document ID: US20250375391A1
- Status: Published application
- Kind: A1
- Application number: 19/099,108
- Filed: 2023-07-28
- Published: 2025-12-11
- Earliest claimed: 2022-07-29
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Yue HUI; Jaclyn MILTON; Mohindra SEEPERSAUD; Karthik RAMACHANDRAN; Russell B. UMSTEAD; Juneyoung LEE; Jun Yong KIM; Calvin Loishiye MARAMBO
- Web page: https://patentgrep.com/patent/US20250375391A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5192: {Processes}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 31/14: for RNA viruses
- C08G 73/0233: {Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

## Claims

### Claim 1

A neutral polymer (NeP) surface lipid, wherein the NeP surface lipid is of Formula (NeP-Ia):
or a salt thereof, wherein:
R3 is —ORO or —SRO;
RO is hydrogen, C1-6 alkyl, phenyl, or an oxygen protecting group;
n is 1 or 2;
R4 is C1-6 alkyl;
r is an integer between 1 and 110, inclusive;
L1 is optionally substituted C1-10 alkylene, wherein at least one methylene of the optionally substituted C1-10 alkylene is independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
D is a moiety obtained by click chemistry, a moiety cleavable under physiological conditions, or is absent;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
A is
each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
each instance of R2 is independently optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of R2 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
p is 1 or 2.

### Claim 2

A lipid assembly, comprising an ionizable lipid, a neutral polymer (NeP) surface lipid, and a structural lipid, wherein the NeP surface lipid is of Formula (NeP-Ia):
or a salt thereof, wherein:
R3 is —ORO or —SRO;
RO is hydrogen, C1-6 alkyl, phenyl, or an oxygen protecting group;
n is 1 or 2;
R4 is C1-6 alkyl;
r is an integer between 1 and 110, inclusive;
L1 is optionally substituted C1-10 alkylene, wherein at least one methylene of the optionally substituted C1-10 alkylene is independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
D is a moiety obtained by click chemistry, a moiety cleavable under physiological conditions, or is absent;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
A is
each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
each instance of R2 is independently optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of R2 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
p is 1 or 2.

### Claim 3

A population of lipid assemblies, comprising an ionizable lipid, a neutral polymer (NeP) surface lipid, and a structural lipid, wherein the NeP surface lipid is of Formula (NeP-Ia):
or a salt thereof, wherein:
R3 is —ORO or —SRO;
RO is hydrogen, C1-6 alkyl, phenyl, or an oxygen protecting group;
n is 1 or 2;
R4 is C1-6 alkyl;
r is an integer between 1 and 110, inclusive;
L1 is optionally substituted C1-10 alkylene, wherein at least one methylene of the optionally substituted C1-10 alkylene is independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
D is a moiety obtained by click chemistry, a moiety cleavable under physiological conditions, or is absent;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
A is
each instance of L2 is independently a bond or an optionally substituted C1-6 alkylene, wherein one methylene unit of the optionally substituted C1-6 alkylene is optionally replaced with —O—, —N(RN)—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, or —NRNC(O)N(RN)—;
each instance of R2 is independently optionally substituted C1-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of R2 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—;
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
Ring B is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
p is 1 or 2.

### Claim 4 (depends on 1, 2, 3)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 3, wherein the NeP surface lipid is of Formula (NeP-Ib):
or a salt thereof.

### Claim 5

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of the preceding claims, wherein A is

### Claim 6

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of the preceding claims, wherein the NeP surface lipid is of Formula (NeP-Ic):
or a salt thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 5, wherein the NeP surface lipid is of Formula (NeP-Id):
or a salt thereof.

### Claim 8

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of the preceding claims, wherein R3 is —OH.

### Claim 9

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of the preceding claims, wherein each instance of R2 is independently C1-30 alkyl or C1-30 alkenyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 8)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 6, 8, and 9, wherein the NeP surface lipid is of the formula:
or a salt thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 8, 9, 10)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 6 and 8 to 10, wherein the NeP surface lipid is,
or a salt thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 7, 8, 9)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 5 and 7 to 9, wherein the NeP surface lipid is
or a salt thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 7, 8, 9)

The NeP surface lipid, the lipid assembly, or the population of lipid assemblies of any one of claims 1 to 5, 7 to 9, and 12, wherein the NeP surface lipid is
or a salt thereof.

### Claim 14 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 13, comprising about 30 mol % to about 50 mol %, about 30 mol % to about 45 mol %, about 30 mol % to about 40 mol %, about 35 mol % to about 45 mol %, or about 35 mol % to about 40 mol % of the ionizable lipid; and/or
comprising about 30 mol %, about 35 mol %, about 40 mol %, about 45 mol %, or about 50 mol % of the ionizable lipid; and/or
wherein the ionizable lipid is compound 301 or compound 22.

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 14, comprising about 15 mol % to about 45 mol %, about 20 mol % to about 45 mol %, about 25 mol % to about 45 mol %, about 30 mol % to about 45 mol %, about 35 mol % to about 45 mol %, or about 40 mol % to about 45 mol % of the structural lipid; and/or
comprising about 15 mol %, about 20 mol %, about 25 mol %, about 30 mol %, about 35 mol %, about 40 mol %, or about 45 mol % of the structural lipid; and/or
wherein the structural lipid is cholesterol.

### Claim 16 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 15, further comprising a phospholipid; optionally:
comprising about 10 mol % to about 30 mol %, 10 mol % to about 25 mol %, 10 mol % to about 20 mol %, about 15 mol % to about 25 mol %, or about 15 mol % to about 20 mol % of the phospholipid; and/or
comprising about 10 mol %, about 15 mol %, about 18 mol %, about 20 mol %, about 22 mol %, about 25 mol %, or about 30 mol % of the phospholipid; and/or
wherein the phospholipid is DSPC, DOPE, DOPC, POPE, POPC, or a combination thereof.

### Claim 17 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 16, further comprising a phosphatidylserine phospholipid; optionally:
comprising between about 1 mol % to about 10 mol %, about 1 mol % to about 8 mol %, about 1 mol % to about 5 mol %, or about 2 mol % to about 5 mol % of the phosphatidylserine phospholipid; and/or
comprising about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, or about 5 mol % of the phosphatidylserine phospholipid.

### Claim 18 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 17, being free of PEG lipid.

### Claim 19 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 17, further comprising a PEG lipid; optionally:
comprising about 0.5 mol % to about 10 mol %, about 0.5 mol % to about 5 mol %, about 1 mol % to about 5 mol %, or about 1 mol % to about 3 mol % of the PEG lipid; and/or
comprising about 0.5 mol %, about 1 mol %, about 2 mol %, about 3 mol %, about 4 mol %, or about 5 mol % of the PEG lipid; and/or
wherein the PEG lipid is PL-02.

### Claim 20 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 19, having a pH value lower than the pKa value of the ionizable lipid; and/or
having a pH value of about 4.0±2.0, about 4.0±1.5, about 4.0±1.4, about 4.0±1.3, about 4.0±1.2, about 4.0±1.1, about 4.0±1.0, about 4.0±0.9, about 4.0±0.8, about 4.0±0.7, about 4.0±0.6, about 4.0±0.5, about 4.0±0.4, about 4.0±0.3, about 4.0±0.2, or about 4.0±0.1; or
having a pH value of about 5.0±2.0, about 5.0±1.5, about 5.0±1.4, about 5.0±1.3, about 5.0±1.2, about 5.0±1.1, about 5.0±1.0, about 5.0±0.9, about 5.0±0.8, about 5.0±0.7, about 5.0±0.6, about 5.0±0.5, about 5.0±0.4, about 5.0±0.3, about 5.0±0.2, or about 5.0±0.1.

### Claim 21 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 19, having a pH value higher than the pKa value of the ionizable lipid; and/or
having a pH value of about 8.0±2.0, about 8.0±1.5, about 8.0±1.4, about 8.0±1.3, about 8.0±1.2, about 8.0±1.1, about 8.0±1.0, about 8.0±0.9, about 8.0±0.8, about 8.0±0.7, about 8.0±0.6, about 8.0±0.5, about 8.0±0.4, about 8.0±0.3, about 8.0±0.2, or about 8.0±0.1; or
having a pH value of about 9.0±3.0, about 9.0±2.0, about 9.0±1.5, about 9.0±1.4, about 9.0±1.3, about 9.0±1.2, about 9.0±1.1, about 9.0±1.0, about 9.0±0.9, about 9.0±0.8, about 9.0±0.7, about 9.0±0.6, about 9.0±0.5, about 9.0±0.4, about 9.0±0.3, about 9.0±0.2, or about 9.0±0.1; or
having a pH value of about 12.0±2.0, about 12.0±1.5, about 12.0±1.4, about 12.0±1.3, about 12.0±1.2, about 12.0±1.1, about 12.0±1.0, about 12.0±0.9, about 12.0±0.8, about 12.0±0.7, about 12.0±0.6, about 12.0±0.5, about 12.0±0.4, about 12.0±0.3, about 12.0±0.2, or about 12.0±0.1.

### Claim 22 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 21, having a zeta potential between about −40 mV to about −5 mV, about −30 mV to about −5 mV, about −20 mV to about −5 mV, about −40 mV to about −10 mV, about −30 mV to about −10mv, or about −20 mV to about −10 mV when measured in 0.1N PBS at pH 7.5.

### Claim 23 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 22, being free of therapeutic agent.

### Claim 24 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The lipid assembly or the population of lipid assemblies of any one of claims 2 to 22, further comprising a therapeutic agent; optionally wherein the therapeutic agent is an RNA.

### Claim 25 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A pharmaceutical composition comprising the lipid assembly or the population of lipid assemblies of any one of claims 2 to 24 and one or more pharmaceutically acceptable carriers or excipients.

### Claim 26 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of preparing the lipid assembly or the population of lipid assemblies of any one of claims 2 to 24.

### Claim 27 (depends on 25)

A method of preparing the pharmaceutical composition of claim 25.

### Claim 28 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject, comprising administering to the subject the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25.

### Claim 29 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25 for use in delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject.

### Claim 30 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25 in the manufacture of a medicament for delivering a therapeutic agent to a hematopoietic stem and progenitor cell (HSPC) in a subject.

### Claim 31 (depends on 28, 29, 30)

The method, lipid assembly, population, pharmaceutical composition, or use of any one of claims 28 to 30, wherein:
the HSPC is in the spleen of the subject; or
the HSPC is in the bone marrow of the subject.

### Claim 32 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating or preventing a disease or disorder, the method comprising administering to a subject in need thereof the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25.

### Claim 33 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25 for use in treating or preventing a disease or disorder in a subject.

### Claim 34 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of the lipid assembly, the population of lipid assemblies, or the pharmaceutical composition of any one of claims 2 to 25 in the manufacture of a medicament for treating or preventing a disease or disorder in a subject.

### Claim 35 (depends on 32, 33, 34)

The method, lipid assembly, population, pharmaceutical composition, or use of any one of claims 32 to 34, wherein:
the subject is human; and/or
the disease or disorder is a spleen disease or a spleen disorder; or
the disease or disorder is a bone marrow disease or a bone marrow disorder.
